COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness.
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
03
01
2022
revised:
10
02
2022
accepted:
16
02
2022
pubmed:
19
3
2022
medline:
24
3
2022
entrez:
18
3
2022
Statut:
ppublish
Résumé
Despite tremendous efforts, worldwide COVID-19 vaccination coverage is lagging. Dose-sparing strategies for COVID-19 vaccines can increase vaccine availability to address the global crisis. Several clinical trials evaluating dose sparing are currently underway. However, to rapidly provide solid scientific justification for different dose-sparing strategies, joint coordinated action involving both public and private parties is needed. In this Viewpoint, we provide examples of approaches to vaccine dose-sparing that have previously been evaluated in clinical trials to improve vaccine availability and reflect on the origin of their funding. With a focus on the current COVID-19 pandemic, we stress the need for expedited testing of vaccine dose-sparing strategies in endemic or epidemic infectious diseases. However, we argue that the establishment of a mechanism through which dose-sparing opportunities are systematically identified, scientifically tested, and ultimately implemented will prove to be valuable beyond the current pandemic for infectious diseases product development and pandemic preparedness in the future.
Identifiants
pubmed: 35303466
pii: S2214-109X(22)00075-4
doi: 10.1016/S2214-109X(22)00075-4
pmc: PMC8923677
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Influenza Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e570-e573Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
Lancet Respir Med. 2021 Nov;9(11):1255-1265
pubmed: 34391547
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Nat Med. 2021 Aug;27(8):1321-1323
pubmed: 34226735
NPJ Vaccines. 2021 Apr 14;6(1):54
pubmed: 33854072
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
Lancet. 2021 Jul 10;398(10295):121-130
pubmed: 34181880
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Travel Med Infect Dis. 2019 Mar - Apr;28:3-5
pubmed: 30878310
N Engl J Med. 2021 Apr 8;384(14):1281-1283
pubmed: 33830709
Med J Aust. 2021 Aug 16;215(4):149-151.e1
pubmed: 34296443
Science. 2021 Oct 22;374(6566):eabj9853
pubmed: 34519540
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Travel Med Infect Dis. 2020 Sep - Oct;37:101868
pubmed: 32898704
Expert Rev Vaccines. 2019 Feb;18(2):119-131
pubmed: 30689472
N Engl J Med. 2019 Aug 1;381(5):444-454
pubmed: 29443626
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Vaccine. 2021 May 12;39(20):2791-2799
pubmed: 33707061
Nat Rev Immunol. 2021 May;21(5):330-335
pubmed: 33795856
Lancet. 2021 Sep 11;398(10304):981-990
pubmed: 34480858
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428